Decitabine
- Generic Name
- Decitabine
- Brand Names
- Dacogen, Inqovi 5 Tablet Pack
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O4
- CAS Number
- 2353-33-5
- Unique Ingredient Identifier
- 776B62CQ27
- Background
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment option...
- Indication
Decitabine is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), as well as for MDS scored ...
- Associated Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Associated Therapies
- -
Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 196
- Registration Number
- NCT04123392
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT04113616
- Locations
- 🇩🇪
University Hospital Jena, Jena, Germany
🇧🇪Cliniques universitaires Saint-Luc, Brussels, Belgium
🇧🇪UZ Gent, Ghent, Belgium
Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 196
- Registration Number
- NCT04098653
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2023-01-06
- Target Recruit Count
- 140
- Registration Number
- NCT04097470
- Locations
- 🇧🇪
BE-Haine-Saint-Paul-JOLIMONT, Haine-Saint-Paul, Belgium
🇨🇭CH-Bellinzona-IOSI, Bellinzona, Switzerland
🇧🇪BE-Antwerpen-ZNASTUIVENBERG, Antwerpen, Belgium
Effect of Food on the Pharmacokinetics of Decitabine/Tetrahydrouridine Combination Capsules in Healthy Adult Subjects
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- EpiDestiny, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT04086238
- Locations
- 🇺🇸
Worldwide Clinical Trial, San Antonio, Texas, United States
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
- Conditions
- Interventions
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 14
- Registration Number
- NCT04055844
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Washington University Medical School, Saint Louis, Missouri, United States
GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Yale University
- Target Recruit Count
- 1
- Registration Number
- NCT04051996
- Locations
- 🇺🇸
Yale Cancer Center/Smilow, New Haven, Connecticut, United States
Biomarker Guided Treatment in DLBCL
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 128
- Registration Number
- NCT04025593
- Locations
- 🇨🇳
Ruijin hospital, Shanghai, Shanghai, China
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT03974217
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 54
- Registration Number
- NCT03969446
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.